These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31366412)

  • 21. Amantadine hydrochloride treatment in olivopontocerebellar atrophy: a long-term follow-up study.
    Botez MI; Botez-Marquard T; Elie R; Le Marec N; Pedraza OL; Lalonde R
    Eur Neurol; 1999; 41(4):212-5. PubMed ID: 10343152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pantothenate kinase-associated neurodegeneration: insights from a Drosophila model.
    Wu Z; Li C; Lv S; Zhou B
    Hum Mol Genet; 2009 Oct; 18(19):3659-72. PubMed ID: 19602483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination.
    Rotheram-Fuller E; De La Garza R; Mahoney JJ; Shoptaw S; Newton TF
    Psychiatry Res; 2007 Aug; 152(2-3):205-10. PubMed ID: 17449110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
    Graham KA; Gu H; Lieberman JA; Harp JB; Perkins DO
    Am J Psychiatry; 2005 Sep; 162(9):1744-6. PubMed ID: 16135638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 26. Pantothenate - kinase associated neurodegeneration.
    Parmar A; Khare S; Srivastav V
    J Assoc Physicians India; 2012 Apr; 60():74-6. PubMed ID: 23029753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabis Use in Children With Pantothenate Kinase-Associated Neurodegeneration.
    Wilson JL; Gregory A; Wakeman K; Freed A; Rai P; Roberts C; Hayflick SJ; Hogarth P
    J Child Neurol; 2020 Mar; 35(4):259-264. PubMed ID: 31823681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postural control, gait, and dopamine functions in parkinsonian movement disorders.
    Bohnen NI; Cham R
    Clin Geriatr Med; 2006 Nov; 22(4):797-812, vi. PubMed ID: 17000336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinico-neurophysiologic and experimental study of the peculiarities of adamantan-sulphate treatment in Parkinson's disease].
    Avakian GN; Voronina TA; Val'dman EA; Nerobkova LN; Katunina EA; Samoĭlova EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(9):18-22. PubMed ID: 15490936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
    Zhang LL; Canning SD; Wang XP
    Curr Neuropharmacol; 2016; 14(4):302-6. PubMed ID: 26635194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Siblings with the adult-onset slowly progressive type of pantothenate kinase-associated neurodegeneration and a novel mutation, Ile346Ser, in PANK2: clinical features and (99m)Tc-ECD brain perfusion SPECT findings.
    Doi H; Koyano S; Miyatake S; Matsumoto N; Kameda T; Tomita A; Miyaji Y; Suzuki Y; Sawaishi Y; Kuroiwa Y
    J Neurol Sci; 2010 Mar; 290(1-2):172-6. PubMed ID: 20006850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN).
    Hogarth P; Kurian MA; Gregory A; Csányi B; Zagustin T; Kmiec T; Wood P; Klucken A; Scalise N; Sofia F; Klopstock T; Zorzi G; Nardocci N; Hayflick SJ
    Mol Genet Metab; 2017 Mar; 120(3):278-287. PubMed ID: 28034613
    [No Abstract]   [Full Text] [Related]  

  • 33. Amantadine for executive dysfunction syndrome in patients with dementia.
    Drayton SJ; Davies K; Steinberg M; Leroi I; Rosenblatt A; Lyketsos CG
    Psychosomatics; 2004; 45(3):205-9. PubMed ID: 15123844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients.
    Silver H; Goodman C; Isakov V; Knoll G; Modai I
    Int Clin Psychopharmacol; 2005 Nov; 20(6):319-26. PubMed ID: 16192841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An 8-year-old boy with gait disturbance and the rapid increase of muscle tonus.
    Yamashita S
    Neuropathology; 2010 Dec; 30(6):661-4. PubMed ID: 20667019
    [No Abstract]   [Full Text] [Related]  

  • 36. Amantadine for migraine.
    Kawase Y; Ikeda K; Iwasaki Y
    Headache; 2008 Oct; 48(9):1380. PubMed ID: 18547263
    [No Abstract]   [Full Text] [Related]  

  • 37. Combined use of electroconvulsive therapy and amantadine in adolescent catatonia precipitated by cyber-bullying.
    Goetz M; Kitzlerova E; Hrdlicka M; Dhossche D
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):228-31. PubMed ID: 23607413
    [No Abstract]   [Full Text] [Related]  

  • 38. Amantadine and pneumonia in elderly stroke patients.
    Teramoto S; Matsuse T; Ouchi T
    Lancet; 1999 Jun; 353(9170):2156; author reply 2157. PubMed ID: 10382719
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel gene mutation in PANK2 in a patient with severe jaw-opening dystonia.
    Yapici Z; Akcakaya NH; Tekturk P; Iseri SA; Ozbek U
    Brain Dev; 2016 Sep; 38(8):755-8. PubMed ID: 27185474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved neurological function after Amantadine treatment in two patients with brain injury.
    Wu TS; Garmel GM
    J Emerg Med; 2005 Apr; 28(3):289-292. PubMed ID: 15769570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.